<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="713">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151874</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ROM-2020-135</org_study_id>
    <nct_id>NCT05151874</nct_id>
  </id_info>
  <brief_title>Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)</brief_title>
  <acronym>ROM-ICTUS</acronym>
  <official_title>Valuation of the Evolution of Passive Mobility (ROM)in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®) in Patients With Post-stroke Spasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the objective measurement of passive joint mobility (ROM) in the spastic upper limb&#xD;
      with Jost's pattern III in patients with post-stroke spasticity after infiltration with&#xD;
      BoNT-A allows to objectify the increase in passive joint balance (ROM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Changes in joint mobility in patients with post-stroke upper limb spasticity after&#xD;
      infiltration of botulinum toxin type A.&#xD;
&#xD;
      The spasticity pattern that will be evaluated will be pattern number III based on the&#xD;
      classification of Jost et al. Joint mobility will be measured with the Lynx instrument&#xD;
      (DyCare)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in passive range of motion</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Change in passive joint mobility (ROM) of the upper limb affected by spasticity pattern III a 20-week follow-up.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Spasticity, Muscle</condition>
  <condition>Stroke Sequelae</condition>
  <condition>Movement Disorders</condition>
  <arm_group>
    <arm_group_label>Range of movement</arm_group_label>
    <description>Change in passive joint mobility (ROM) of the carpus (flexion-extension) affected by spasticity pattern III during a 20-week follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abobotulinum toxin A</intervention_name>
    <description>To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.</description>
    <arm_group_label>Range of movement</arm_group_label>
    <other_name>toxin infiltration</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged ≥ 18 years.&#xD;
&#xD;
        Hemiplegic patients with post-stroke upper limb spasticity affected by pattern III1 who&#xD;
        have undergone at least 2 cycles of previous treatment with BoNT-A&#xD;
&#xD;
        Patients with a MAS scale (Modified Ashworth Scale) between 2 and 3 for the affected muscle&#xD;
        group; shoulder, elbow, carpus and metacarpophalangeal.&#xD;
&#xD;
        Patients with Hackett ultrasound qualitative scale between 2 and 3 for the affected muscle&#xD;
        group; shoulder, elbow, carpus and metacarpophalangeal.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥ 18 years.&#xD;
&#xD;
          -  Hemiplegic patients with post-stroke upper limb spasticity affected by pattern III1&#xD;
             who have undergone at least 2 cycles of previous treatment with BoNT-A&#xD;
&#xD;
          -  Patients with a MAS scale (Modified Ashworth Scale) between 2 and 3 for the affected&#xD;
             muscle group; shoulder, elbow, carpus and metacarpophalangeal.&#xD;
&#xD;
          -  Patients with Hackett ultrasound qualitative scale between 2 and 3 for the affected&#xD;
             muscle group; shoulder, elbow, carpus and metacarpophalangeal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not wish to sign the informed consent.&#xD;
&#xD;
          -  Prior lack of primary or secondary response to any BoNT-A for any specific condition&#xD;
             or known sensitivity to BoNT-A or any excipient.&#xD;
&#xD;
          -  Routine or prescribed treatment with any medication that directly or indirectly&#xD;
             interferes with neuromuscular function in the last 3 months prior to study botulinum&#xD;
             toxin treatment.&#xD;
&#xD;
          -  Having undergone surgery on the muscles, ligaments, tendons, nerves or bones of the&#xD;
             limb to be treated.&#xD;
&#xD;
          -  Any medical condition or analytical finding that, in the opinion of the investigator,&#xD;
             may compromise compliance with the objectives and / or procedures of the study&#xD;
             protocol or exclude the administration of BoNT-A.&#xD;
&#xD;
          -  Treatment with an investigational new drug in the 4 weeks or 5 half-lives prior to&#xD;
             screening to enter the study.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Helena Bascuñana, Dr</last_name>
      <phone>+34 935537059</phone>
      <email>hbascunana@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Eliot Ramirez, Dr</last_name>
      <phone>+34 935537059</phone>
      <email>eramirezm@santpau.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spasticity</keyword>
  <keyword>Abobotulinum toxin</keyword>
  <keyword>Injection</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

